



Press release  
March 31, 2014 – 05:35 pm CET

## Cardio3 BioSciences Appoints Hanspeter Spek, Senior Pharmaceutical Executive to its Board of Directors

**Mont-Saint-Guibert, Belgium,** - Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, today announces it intends to appoint Hanspeter Spek as a Non- Executive Director. The appointment is expected to be formalized at C3BS' next general assembly on May 5<sup>th</sup> 2014.

Hanspeter started his career at Pfizer where, over more than ten years and after a thorough comprehensive training in commercial general management, he held positions of increasing responsibility. He then joined Sanofi as Marketing Director and rose through the organization to become the Executive Vice President International in 2000. When Sanofi and Aventis merged in 2004, he took on the responsibility of Executive Vice President Operations. In 2009, he was nominated President Global Operations. He retired from Sanofi in mid-2013. He has since joined Advent as a Senior Advisor for Healthcare. He continues to serve on the Board of Sanofi, Germany, as Chairman.

**Dr Christian Homsy, CEO of Cardio3 BioSciences comments:** "We are extremely proud that an executive of the caliber of Hanspeter has decided to join the Board of C3BS, reflecting our leadership in our field. His extensive experience in building partnerships and leading operations, marketing and sales will be invaluable in best preparing our company to commercialize C-Cure<sup>®</sup>. As a member of the Executive Committee at Sanofi, Hanspeter has been a key participant in numerous partnerships, acquisitions and licensing deals, and, as such, he will further enhance our capability to pursue business development opportunities and allow us to benefit from his perspective as a large healthcare industry executive."

**Commenting on his new role, Hanspeter Spek said:** "I am honored to have the opportunity to contribute to the future development of C3BS. With the CHART-1 Phase III program running in Europe and approval to commence CHART-2 from the US FDA, the Company is positioned at the forefront of regenerative medicine. Heart disease remains an area of substantial unmet medical need and I look forward to bringing my experience of development, launch preparation and worldwide commercialization to the Board and to working with the team to deliver on C-Cure's potential."

\*\*\* END \*\*\*

For more information contact:

**Cardio3 BioSciences**

Dr Christian Homsy, CEO

Anne Portzenheim, Communication Manager

[www.c3bs.com](http://www.c3bs.com)

Tel : +32 10 39 41 00

[aportzenheim@c3bs.com](mailto:aportzenheim@c3bs.com)

**Citigate Dewe Rogerson**

Chris Gardner

Tel : +44 (0) 207 638 9571



## About Cardio3 BioSciences

Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.

The Company's lead product candidate C-Cure<sup>®</sup> is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure<sup>®</sup> consists of a patient's own cells that are harvested from the patient's bone marrow and engineered to become new heart muscle cells that behave identically to those lost to heart disease. This process is known as Cardiopoiesis.

Cardio3 BioSciences has also developed C-Cath<sup>®<sub>ez</sub></sup>, the most technologically advanced injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.

Cardio3 BioSciences' shares are listed on NYSE Euronext Brussels and NYSE Euronext Paris under the ticker symbol CARD.

*C3BS-CQR-1, C-Cure, C-Cath, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities. As a result, of these factors investors and prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or review any forward-looking statement, whether as a result of new information, future events or otherwise.*

---

---